A 3-part Phase 1, Randomized, Double-blind, Sponsor-Open, Placebo Controlled Trial To Evaluate The Safety, Tolerability, Food Effect, Pharmacokinetics And Pharmacodynamics Of PF-06751979 After Oral Administration: Part A - Single Ascending Doses In Healthy Adults; Part B - Multiple Ascending Doses In Healthy Adults; And Part C - Multiple Doses To Elderly Subjects

Trial Profile

A 3-part Phase 1, Randomized, Double-blind, Sponsor-Open, Placebo Controlled Trial To Evaluate The Safety, Tolerability, Food Effect, Pharmacokinetics And Pharmacodynamics Of PF-06751979 After Oral Administration: Part A - Single Ascending Doses In Healthy Adults; Part B - Multiple Ascending Doses In Healthy Adults; And Part C - Multiple Doses To Elderly Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs PF 6751979 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Feb 2017 Status changed from recruiting to completed.
    • 04 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Jan 2017.
    • 04 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top